To the Editor:
Erosive lichen planus (LP) often is painful, debilitating, and resistant to topical therapy making it both a diagnostic and therapeutic challenge. We report the case of an elderly woman with isolated perianal erosive LP, a rare clinical manifestation. We also review cases of erosive perianal LP reported in the literature.

A 72-year-old woman was referred to our dermatology clinic for evaluation of multiple pruritic and painful perianal lesions of 1 year’s duration. The lesions had remained stable since onset, with no other reported lesions elsewhere on body, including the mucosae. Her medical history was notable for rheumatoid arthritis, osteoporosis, hypercholesterolemia, and hypertension. She was taking methotrexate, folic acid, abatacept, alendronate, atorvastatin, and lisinopril. The patient reported she had been using abatacept for 3 years and lisinopril for 2 years. Her primary care physician initially treated the lesions as hemorrhoids but referred her to a gastroenterologist when they failed to improve. Gastroenterology evaluated the patient, and a colonoscopy was performed with unremarkable results. Thus, she was referred to dermatology for further evaluation.

Physical examination revealed 2 tender, sharply defined, angulated erosions with irregular violaceous borders involving the perianal skin (Figure 1). A biopsy of one of the lesions was taken. Histopathologic examination revealed acanthosis of the epidermis with slight compact hyperkeratosis, scattered dyskeratotic keratinocytes, and a dense bandlike lymphohistiocytic infiltrate that obliterated the dermoepidermal junction (Figure 2). A diagnosis of perianal erosive LP was made. The patient

PRACTICE POINTS
- Erosive lichen planus (LP) is an underrecognized variant of LP presenting with painful erosions, ulcerations, and scarring.
- Although rare, perianal erosive LP should be included in the differential diagnosis of perianal erosions.
- Treatment with high-potency steroids is an effective therapeutic option resulting in notable improvement.

Figure 1. Sharply defined and angulated erosions with irregular borders (arrows).
was prescribed mometasone ointment 0.1% daily with notable improvement after 2 months.

Erosive LP is an extremely rare variant of LP.\(^1\) It typically manifests as chronic painful erosions that often can progress to scarring, ulceration, and tissue destruction. Although erosive LP most commonly involves the mucosal surfaces of the genitalia and oral mucosa, it also has been reported in the palmoplantar skin, lacrimal duct, external auditory meatus, and esophagus.\(^2\)\(^-\)\(^7\) However, isolated perianal involvement is extremely rare. A PubMed search of articles indexed for MEDLINE using the terms erosive or ulcerative and lichen planus and perianal revealed 10 cases of perianal erosive LP, and weak data exist regarding therapy (Table).\(^8\)\(^-\)\(^12\) Of these

![Figure 2](image1)

**Figure 2.** A, Histopathologic examination revealed acanthosis of the epidermis with slight compact hyperkeratosis, scattered dyskeratotic keratinocytes, and a dense bandlike lymphohistiocytic infiltrate that obliterated the dermoepidermal junction (H&E, original magnification ×10). B, A Civatte body was observed (arrow) (H&E, original magnification ×20).

### Summary of Cases of Erosive Perianal Lichen Planus

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Age, y</th>
<th>Sex</th>
<th>Location</th>
<th>Time of evolution</th>
<th>Treatment</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payne et al(^8) (1997)</td>
<td>35–60</td>
<td>4 M; 2 F</td>
<td>1 case isolated to the perianal region; the other cases not specified if perianal only</td>
<td>6 wk to 8 y</td>
<td>Clobetasol propionate ointment 0.05% BID for 3 wk</td>
<td>Good response</td>
</tr>
<tr>
<td>Watsky et al(^9) (2003)</td>
<td>46</td>
<td>M</td>
<td>Perianal region</td>
<td>2–3 y</td>
<td>Halobetasol ointment for 10 wk, recurred 1 year later; then tacrolimus ointment 0.1% for 1 mo, no recurrence</td>
<td>Folliculitis developed after halobetasol, treated with topical clindamycin</td>
</tr>
<tr>
<td>Scheiba et al(^10) (2014)</td>
<td>49</td>
<td>M</td>
<td>Perianal region</td>
<td>Several months</td>
<td>NR</td>
<td>Hypertrophic, slightly erosive perianal LP</td>
</tr>
<tr>
<td>Wu et al(^11) (2014)</td>
<td>32</td>
<td>F</td>
<td>Gums, vulva, perianal region</td>
<td>8 y</td>
<td>Topical tacrolimus for 3 wk with notable improvement</td>
<td>Vulvovaginal gingival syndrome</td>
</tr>
<tr>
<td>Hammami et al(^12) (2015)</td>
<td>52</td>
<td>M</td>
<td>Tongue, glans penis, perianal region</td>
<td>Days (NS)</td>
<td>Systemic steroids</td>
<td>LP induced by glimepiride</td>
</tr>
<tr>
<td>Current case</td>
<td>72</td>
<td>F</td>
<td>Perianal region</td>
<td>1 y</td>
<td>Mometasone ointment 0.1%</td>
<td>Clinical remission</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female; BID, twice daily; NR, not reported; LP, lichen planus; NS, not specified.
EROSIVE LP

cases, only 3 reported isolated perianal involvement. In most reported cases, perianal involvement manifested as extremely painful and occasionally pruritic, sharply angulated erosions and ulcers arising 0.5 to 3 cm from the anus with macerated, whitish, and violaceous borders. Most of the lesions occurred unilaterally, with only 1 case of bilateral perianal involvement.

The differential diagnosis of perianal erosions is extensive and includes cutaneous Crohn disease, extramammary Paget disease, cutaneous malignancy, herpes simplex virus, cytomegalovirus, external hemorrhoids, lichen sclerosus, Behçet disease, lichen simplex chronicus, and drug-induced lichenoid reaction, among others. It is worth emphasizing infectious processes and cutaneous malignancies in light of our patient’s immunosuppression. Perianal cytomegalovirus has been reported in the literature in association with HIV, and it is a clinically challenging diagnosis. Cutaneous malignancy associated with the use of methotrexate also was considered in the differential diagnosis for our patient, given the increased risk for nonmelanoma skin cancer with the use of immunosuppressants.

Along with a thorough patient history and physical examination, skin biopsy and clinicopathologic correlation are key to determine the exact etiology. Histologically, LP is characterized by a lichenoid interface dermatitis with a dense bandlike lymphohistiocytic infiltrate at the dermoepidermal junction. Other distinguishing factors include irregular acanthosis, hyperkeratosis, basal cell vacuolar degeneration, and Civatte bodies. Drug-induced LP is a possibility, but it is unclear if abatacept or lisinopril may have played a role in our patient. However, absence of eosinophils and parakeratosis suggested an idiopathic rather than drug-induced etiology. In 2016, Day et al published a clinicopathologic review of 60 cases of perianal lichenoid dermatoses in which only 17% of lesions were LP. Of note, 90% of perianal LP lesions were of the hypertrophic variant, and none were of the erosive variant, further supporting that our case represents a rare clinical manifestation of perianal LP.

Treatment of LP varies depending on the location and subtype of the lesions and is primarily aimed at improving symptoms. Topical corticosteroids are the standard treatment of LP; however, there is limited evidence regarding their efficacy for mucosal LP. Although randomized controlled trials assessing the efficacy of different interventions on oral erosive LP are available in the literature, there is a paucity of studies addressing this topic for genital or perianal LP. A review of the literature regarding perianal erosive LP suggests good response to high-potency topical steroids and calcineurin inhibitors with resolution of lesions within 3 to 4 weeks.

EROSIVE LP is a painful variant that can cause erosions, ulcerations, and scarring. It rarely is seen in the perianal region alone and presents a diagnostic challenge. Treatment with high-potency topical steroid therapy seems to be effective in the few cases that have been reported as well as in our case. More comprehensive data from randomized controlled trials would be needed to evaluate their efficacy compared to other therapies.

REFERENCES